Figure 2
From: SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity
PEN-221 treatment mediates SSTR2-dependent elimination of Jurkat xenografts in vivo. (a) Schematic of the bilateral Jurkat mouse model. Fluc-expressing Jurkat-NT and Jurkat-SSTR2 cells (1 × 106/xenograft) were implanted subcutaneously into opposite flanks of the same NSG-MHC-KO mice and treated with 25 μg of PEN-221 intravenously every 3–4 days from day 35 to day 50 or left untreated. (b) Tumor growth was assessed by bioluminescence imaging on a weekly basis. (c) Tumor burden was estimated by the level of total body bioluminescence intensity (n = 4 for control, and 5 for PEN-221 cohort). Data represent mean ± SD. Statistical significance was determined by unpaired, two-tailed student’s t-test. **, P < 0.01; ns, not significant.
